ライフサイエンスコーパス: pneumococcal polysaccharide vaccine

1 with the conjugate vaccine compared with the pneumococcal polysaccharide vaccine.

2 re due to serotypes covered by the 23-valent pneumococcal polysaccharide vaccine.

3 were serotypes represented in the 23-valent pneumococcal polysaccharide vaccine.

4 lysaccharides used to formulate a polyvalent pneumococcal polysaccharide vaccine.

5 ates were serotypes that are included in the pneumococcal polysaccharide vaccine.

6 9F, and 23F linked to CRM197, or a 23-valent pneumococcal polysaccharide vaccine.

7 f dementia compared to the control 23-valent pneumococcal polysaccharide vaccine.

8 polysaccharide antigens was assessed using a pneumococcal polysaccharide vaccine.

9 pneumonia following receipt of the 23-valent pneumococcal polysaccharide vaccine.

10 long-lasting, impaired antibody responses to pneumococcal polysaccharide vaccines.

11 the influence of Km and Gm allotype genes on pneumococcal polysaccharide vaccines.

12 ons manifest decreased antibody responses to pneumococcal polysaccharide vaccines.

13 A 23-valent unconjugated pneumococcal polysaccharide vaccine (23vP), routinely ad

14 7; Prevnar) in infancy followed by 23-valent pneumococcal polysaccharide vaccine (23vPPV; Pneumovax)

15 stem activation using the standard 23-valent pneumococcal polysaccharide vaccine, (3) daily sampling

16 -treated patients had decreased responses to pneumococcal polysaccharide vaccine (57% of patients had

17 uded in the 7-valent conjugate and 23-valent pneumococcal polysaccharide vaccines accounted for 78 pe

18 s, but it remains unclear whether use of the pneumococcal polysaccharide vaccine alters the overall r

19 697 received 23-valent pneumococcal polysaccharide vaccine and 695 received pla

20 The patient had received 23-valent pneumococcal polysaccharide vaccine and there was no evi

21 rgeting high-risk groups was undertaken with pneumococcal polysaccharide vaccine, and subsequently ra

22 All children received 23-valent pneumococcal polysaccharide vaccine at age 13 months.

23 Four of 16 patients in group 1 responded to pneumococcal polysaccharide vaccine compared with 14 of

24 Immunization with the pneumococcal polysaccharide vaccine does not prevent col

25 The pneumococcal polysaccharide vaccine elicited comparable

26 se findings support the effectiveness of the pneumococcal polysaccharide vaccine for the prevention o

27 Pneumococcal polysaccharide vaccine is recommended for e

28 However, the effect of pneumococcal polysaccharide vaccine on vascular events r

29 e vaccine (PCV) followed by either a dose of pneumococcal polysaccharide vaccine or a fourth PCV dose

30 gate vaccine followed by 1 dose of 23-valent pneumococcal polysaccharide vaccine or a single dose of

31 rted that the 7-valent diphtheria-conjugated pneumococcal polysaccharide vaccine (PCV7) is safe and i

32 administration of the heptavalent conjugated pneumococcal polysaccharide vaccine (PCV7) were also ass

33 We compared revaccination with 23-valent pneumococcal polysaccharide vaccine (PN23) with primary

34 vaccination or revaccination with 23-valent pneumococcal polysaccharide vaccine (PN23).

35 ther passive immunization with the 23-valent pneumococcal polysaccharide vaccine (Pneumovax(R) 23; PP

36 The 23-valent pneumococcal polysaccharide vaccine (Pneumovax) might pr

37 udy murine immune responses to the 23-valent pneumococcal polysaccharide vaccine Pnu-Imune, both in v

38 All received 23-valent pneumococcal polysaccharide vaccine (PPS).

39 dose 6 months later, and 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) 1 month lat

40 jugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 2 months la

41 15-valent PCV (PCV15) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 8 weeks lat

42 gate vaccine (PCV13) compared with 23-valent pneumococcal polysaccharide vaccine (PPSV23) among US ad

43 ortions and incidence matching the 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-vale

44 usly vaccinated with >/= 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) and had CD4

45 rt 1 (n = 350) previously received 23-valent pneumococcal polysaccharide vaccine (PPSV23) and were ra

46 tion Practices has recommended the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for nonelde

47 PD), with the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for prevent

48 Although the 23-valent pneumococcal polysaccharide vaccine (PPSV23) protects ag

49 te vaccine (PCV13) followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) remains unc

50 lent conjugate vaccine [PCV13] and 23-valent pneumococcal polysaccharide vaccine [PPSV23]).

51 Controversy persists over the benefits of pneumococcal polysaccharide vaccine (PPV) for adults at

52 Revaccination of healthy adults with pneumococcal polysaccharide vaccine (PPV) within several

53 The 23-valent pneumococcal polysaccharide vaccine (PPV-23) uptake amon

54 Twenty-three-valent pneumococcal polysaccharide vaccine (PPV-23), which cont

55 umonia (n = 16) and healthy volunteers given pneumococcal polysaccharide vaccine (PPV; n = 14) or pne

56 (PCV13) concurrently, followed by 23-valent pneumococcal polysaccharide vaccine (PPV23) 2 months lat

57 determine the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) among Navajo

58 The benefits of using the 23-valent pneumococcal polysaccharide vaccine (PPV23) are controve

59 grouped serotypes contained in the 23-valent pneumococcal polysaccharide vaccine (PPV23) decreased at

60 Vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV23) is available

61 Since the 23-valent pneumococcal polysaccharide vaccine (PPV23) is less effe

62 In the United Kingdom, the 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommend

63 >/= 200 randomized to receive the 23-valent pneumococcal polysaccharide vaccine (PPV23) or placebo a

64 V (PCV13) vs regions that used the 23-valent pneumococcal polysaccharide vaccine (PPV23) was also ana

65 65 years or older; previously only 23-valent pneumococcal polysaccharide vaccine (PPV23) was recommen

66 and are indications for receipt of 23-valent pneumococcal polysaccharide vaccine (PPV23).

67 althy human adults with Pneumovax (23-valent pneumococcal polysaccharide vaccine [PPV23]), IgG anti-c

68 (PCV) followed by either a dose of 23-valent pneumococcal polysaccharide vaccine (PSV23) or a fourth

69 licensed (23-valent, 25 microgram/serotype) pneumococcal polysaccharide vaccine (PV).

70 e vaccine serotypes and 82.8% with 23-valent pneumococcal polysaccharide vaccine serotypes.

71 The 23-valent pneumococcal polysaccharide vaccine was formulated to pr

72 rs after transplantation and the response to pneumococcal polysaccharide vaccine was significantly lo

73 sera of people immunized with the 23-valent pneumococcal polysaccharide vaccine, we confirmed that h

74 ne response to that induced by the 23-valent pneumococcal polysaccharide vaccine, which has been the

75 eritoneal B1b compartment, immunization with pneumococcal polysaccharide vaccine yielded comparable a